This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.
Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S . Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005; 90: 881–889.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209–2221.
Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179–1181.
Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012; 44: 642–650.
Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood 2015; 126: 2491–2501.
Sun Q-Y, Ding L-W, Tan K-T, Chien W, Anand MT, Lin D-C et al. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia 2016; e-pub ahead of print 8 July 2016 doi:10.1038/leu.2016.160.
Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander SK, Zellmeier E et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009; 144: 517–523.
Krönke J, Schlenk RF, Jensen K-O, Tschürtz F, Corbacioglu A, Gaidzik VI et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011; 29: 2709–2716.
Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al. Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220–2231.
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328–333.
Klco JM, Miller CA, Griffith M et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015; 314: 811–822.
Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci 2014; 111: 2548–2553.
Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol 2014; 167: 478–486.
Wiseman DH, Williams EL, Wilks DP, Sun Leong H, Somerville TD, Dennis MW et al. Frequent reconstitution of IDH2R140Q mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia. Leukemia 2016; 30: 1946–1950.
Acknowledgements
This work was funded by the Singapore Ministry of Health’s National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to HPK, the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative. This study is partially supported by a generous donation from the Melamed family, Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy, and Mr Reuben Yeroushalmi.
Author contributions
WC, Q-YS and L-WD designed the study, performed the experiments, analyzed the data and wrote the manuscript. AM, LL, KTT and HY performed bioinformatics and data analysis. ST, SLL, ADSMV, JX, NJ and KB performed the experiments. MG, CS, ML, VM, NH, SG and SO contributed reagents and assisted with data analysis. SW, TI, L-YS, TA and TH coordinated collection and processing of clinical samples. HPK conceived the project, helped design experiments, analyzed the data and helped to write the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
TH is employed by and partly owns the MLL Munich Leukemia Laboratory. TA is employed by the MLL Munich Leukemia Laboratory. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Chien, W., Sun, QY., Ding, LW. et al. Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD. Leukemia 31, 762–766 (2017). https://doi.org/10.1038/leu.2016.343
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.343
This article is cited by
-
The multifaceted role of reactive oxygen species in tumorigenesis
Cellular and Molecular Life Sciences (2020)
-
A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
Journal of Molecular Medicine (2020)
-
Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3
Current Medical Science (2018)